Numinus Wellness congratulates study team on announcement of results from Phase 3 randomized clinical trial of MDMA-assisted therapy for treatment of severe PTSD
The trial, which involved 90 participants with chronic PTSD, demonstrated that 88% of participants who received three controlled and supervised MDMA-assisted therapy sessions experienced a clinically significant reduction in symptoms, with 67% no longer qualifying for PTSD diagnosis in comparison to 32% of participants randomized to placebo The results, published in the peer-reviewed medical journal Nature Medicine, presented no serious safety concerns, and confirmed earlier findings from MAPS six completed Phase 2 clinical trials that demonstrated clear safety and efficacy of MDMA-assisted therapy
MDMA, magic mushrooms could be the hottest entry in psychiatry, researchers hopeful
Psychedelics could be the newest entry to psychiatric therapies as researchers exploring the therapeutic prowess of the compounds are optimistic about its impact in treating post-traumatic stress disorder.
advertisement
Image for Representation. (Photo: Reuters)
Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), is exploring the healing power of compounds such as LSD, Ecstasy and magic mushrooms in treating mental health disorders in patients, amid anti-drug campaigns that criminalise the use of such substances.
The first Phase 3 clinical trial of Doblin s study conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought substantial relief to patients with severe post-traumatic stress disorder, the New York Times reported. Nature Medicine is also expected to publish results of his lab study on MDMA soon
What is MDMA: party drug or therapeutic agent?
At home in both weekend raves and the psychiatric ward, MDMA is not your typical street drug.
MDMA in pill form (ecstasy) and powder (molly). Credit: Flickr, Kripos NCIS.
MDMA, short for 3,4 methylenedioxymethamphetamine, is a psychoactive drug whose effects can resemble those of both stimulants and psychedelics. The drug is known to produce distortions in time and perception, enhance the enjoyment of sensory experiences, and make people feel more energized. Its defining feature is that it increases self-awareness and empathy, which together enable a feeling of connectedness that many users report.
In its tablet or capsule form, MDMA is known as
May 4, 2021
The popularization of psychedelics has already transformed the American mind. As tripping becomesnormalizedandlegal in the coming decade, the pace of change will only accelerate. There will be more openness to new ideas, both brilliant and insane. Commercial availability will also invigorate the market for synthetic religious experiences.
Having seen people gobble up hallucinogens in various contexts, I’m not particularly bothered by the substances themselves. The physical effects are negligible fatality rates are basically zero and many people derive real insight from their use. Certainly, a sizable minority become head-spun wackos, but compared to the utter devastation wrought by opiates, or even alcohol, it’s a peripheral concern.
From High Times, to facing prison, Matt Stang is now the CEO of a psychedelic company Stang says he lived through the tipping point with cannabis and something similar is happening with psychedelics.
Author of the article: Sam Riches
Publishing date: May 03, 2021 • 4 hours ago • 5 minute read Matt and Jackee Stang, the co-founders of Delic Corp. Photo by Delic Corp
Article content
This story first appeared in Weekend Dispensary, a weekly newsletter from The GrowthOp. Signup now to get a story delivered to your inbox every Saturday.
In 2010, Matt Stang was facing the possibility of spending the rest of his life in prison.